Experimental Hematology
Volume 38, Issue 4 , Pages 270-281 , April 2010

Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation

  • Thomas A. Davis

      Affiliations

    • Department of Regenerative Medicine, Naval Medical Research Center, Silver Spring, Md., USA
    • ,
  • Michael R. Landauer

      Affiliations

    • Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, Md., USA
    • ,
  • Steven R. Mog

      Affiliations

    • Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, Md., USA
    • ,
  • Michal Barshishat-Kupper

      Affiliations

    • Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, Md., USA
    • ,
  • Stephen R. Zins

      Affiliations

    • Department of Regenerative Medicine, Naval Medical Research Center, Silver Spring, Md., USA
    • ,
  • Mihret F. Amare

      Affiliations

    • Department of Regenerative Medicine, Naval Medical Research Center, Silver Spring, Md., USA
    • ,
  • Regina M. Day

      Affiliations

    • Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, Md., USA
    • Corresponding Author InformationOffprint requests to: Regina M. Day, Ph.D., Department of Pharmacology, Uniformed Services University of the Health Sciences, Building C, Room 2023, 4301 Jones Bridge Road, Bethesda, MD 20814-4799

Received 5 January 2010 ,Revised 5 January 2010 ,Accepted 20 January 2010.

References 

  1. Meder J, Michalowski A. Changes in cellularity and/or weight of mouse hemopoietic tissues as a measure of acute radiation effects. Arch Immunol Ther Exp. 1980;28:9–18
  2. Storb R. Allogeneic hematopoietic stem cell transplantation—yesterday, today, and tomorrow. Exp Hematol. 2003;31:1–10
  3. Wagemaker G. Heterogeneity of radiation sensitivity of hemopoietic stem cell subsets. Stem Cells. 1995;13(Suppl 1):257–260
  4. Mouthon MA, Van der Meeren A, Vandamme M, Squiban C, Gaugler MH. Thrombopoietin protects mice from mortality and myelosuppression following high-dose irradiation: importance of time scheduling. Can J Physiol Pharmacol. 2002;80:717–721
  5. Tamulevicius P, Wang M, Iliakis G. Homology-directed repair is required for the development of radioresistance during S phase: interplay between double-strand break repair and checkpoint response. Radiat Res. 2007;167:1–11
  6. Davis TA, Mungunsukh O, Zins S, Day RM, Landauer MR. Genistein induces radioprotection by hematopoietic stem cell quiescence. Int J Radiat Biol. 2008;84:713–726
  7. Greenberger JS, Epperly M. Bone marrow-derived stem cells and radiation response. Semin Radiat Oncol. 2009;19:133–139
  8. Metcalf D. Hematopoietic cytokines. Blood. 2008;111:485–491
  9. Herodin F, Drouet M. Cytokine-based treatment of accidentally irradiated victims and new approaches. Exp Hematol. 2005;33:1071–1080
  10. Stroth U, Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol. 1999;33(Suppl 1):S21–S28discussion S41−S23
  11. Rodgers K, Xiong S, Steer R, DiZerega G. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. 2000;18:287–294
  12. Zambidis ET, Park TS, Yu W, et al. Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood. 2008;112:3601–3614
  13. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension. 2005;45:526–529
  14. Chisi JE, Wdzieczak-Bakala J, Thierry J, Briscoe CV, Riches AC. Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures. Stem Cells. 1999;17:339–344
  15. Chisi JE, Briscoe CV, Ezan E, Genet R, Riches AC, Wdzieczak-Bakala J. Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Br J Haematol. 2000;109:563–570
  16. Rousseau-Plasse A, Wdzieczak-Bakala J, Lenfant M, et al. Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo. Exp Hematol. 1998;26:1074–1079
  17. Ellefson DD, diZerega GS, Espinoza T, Roda N, Maldonado S, Rodgers KE. Synergistic effects of co-administration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice. Cancer Chemother Pharmacol. 2004;53:15–24
  18. Rodgers KE, Xiong S, diZerega GS. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol. 2002;49:403–411
  19. Moulder JE, Cohen EP, Fish BL, Hill P. Prophylaxis of bone marrow transplant nephropathy with captopril, an inhibitor of angiotensin-converting enzyme. Radiat Res. 1993;136:404–407
  20. Charrier S, Michaud A, Badaoui S, et al. Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. Blood. 2004;104:978–985
  21. McPherson C. Reduction of Pseudomonas aeruginosa and coliform bacteria in mouse drinking water following treatment with hydrochloric acid and chlorine. Lab Anim Care. 1963;13:737–744
  22. Davis TA, Clarke TK, Mog SR, Landauer MR. Subcutaneous administration of genistein prior to lethal irradiation supports multilineage, hematopoietic progenitor cell recovery and survival. Int J Radiat Biol. 2007;83:141–151
  23. Escribano G, Torrado D, Torrado D. Stability study of an aqueous formulation of captopril at 1 mg/ml (Spanish). Farm Hosp. 2005;29:30–36
  24. Day R, Barshishat-Kupper M, Mog SR, et al. Genistein protects against biomarkers of delayed lung sequelae in mice surviving high dose total body irradiation. J Radiat Res. 2008;49:361–372
  25. Stickney DR, Dowding C, Garsd A, et al. 5-androstenediol stimulates multilineage hematopoiesis in rhesus monkeys with radiation-induced myelosuppression. Int Immunopharmacol. 2006;6:1706–1713
  26. Rodgers KE, Xiong S, Steer R, diZerega GS. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. 2000;18:287–294
  27. Jokubaitis VJ, Sinka L, Driessen R, et al. Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood. 2008;111:4055–4063
  28. Ferdinand KC, Taylor C. The management of hypertension with angiotensin receptor blockers in special populations. Clin Cornerstone. 2009;9(Suppl 3):S5–S17
  29. Bommer WJ. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2. Prev Cardiol. 2008;11:215–222
  30. Cheng T, Rodrigues N, Shen H, et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science. 2000;287:1804–1808
  31. Glicklich D, Burris L, Urban A, et al. Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis. J Am Soc Nephrol. 2001;12:1958–1964
  32. van Brummelen P, Willemze R, Tan W, et al. Captopril associated agranulocytosis. Lancet. 1980;1:150
  33. Casato M, Pucillo L, Leoni M, et al. Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematological toxicity. Am J Med. 1995;99:386–390
  34. Israeli A, Or R, Leitersdorf E. Captopril-associated transient aplastic anemia. Acta Haematol. 1985;73:106–107
  35. Gavras I, Graff L, Rose B, et al. Fatal pancytopenia associated with the use of captopril. Ann Intern Med. 1981;94:58–59
  36. Na Nakorn T, Traver D, Weissman IL, Akashi K. Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J Clin Invest. 2002;109:1579–1585
  37. Hosseinimehr SJ, Mahmoudzadeh A, Akhlagpour S. Captopril protects mice bone marrow cells against genotoxicity induced by gamma irradiation. Cell Biochem Funct. 2007;25:389–394
  38. Chopra M, Scott N, McMurray J, et al. Captopril: a free radical scavenger. Br J Clin Pharmacol. 1989;27:396–399
  39. Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol. 2005;31:1042–1050
  40. Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists. Curr Pharm Des. 2007;13:1317–1325
  41. Moulder JE, Cohen EP. Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin Radiat Oncol. 2007;17:141–148
  42. Ma J, Shi M, Li J, et al. Senescence-unrelated impediment of osteogenesis from Flk1+ bone marrow mesenchymal stem cells induced by total body irradiation and its contribution to long-term bone and hematopoietic injury. Haematologica. 2007;92:889–896
  43. Dominici M, Rasini V, Bussolari R, et al. Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. Blood. 2009;114:2333–2343
  44. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425:836–841
  45. Kopp HG, Hooper AT, Avecilla ST, Rafii S. Functional heterogeneity of the bone marrow vascular niche. Ann N Y Acad Sci. 2009;1176:47–54
  46. Nilsson SK, Johnston HM, Whitty GA, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood. 2005;106:1232–1239

PII: S0301-472X(10)00012-3

doi: 10.1016/j.exphem.2010.01.004

Experimental Hematology
Volume 38, Issue 4 , Pages 270-281 , April 2010

Article Tools

* Image Usage & Resolution